Cuozzo Speed Technologies, LLC v. Lee, U.S., No. 15-446, amicus brief filed 3/7/2016
File Downloads
All documents are in PDF format.
The Federal Circuit erred in endorsing the PTAB’s use of the broadest reasonable interpretation (BRI) standard for claim construction in AIA trial proceedings, AIPLA argued to the Supreme Court in a March 7, 2016 amicus brief.
The BRI standard was specially crafted for examinational proceedings, not for the adjudicative proceedings created by the AIA. Congress intended those adjudicative proceedings to be an efficient alternative to district court trials, according to the brief, and they should follow the Phillips/Markman standard for claim construction used in district courts. The amicus brief also argued that the Federal Circuit incorrectly bars appellate consideration of issues raised in the PTAB final written decision when those issues were also addressed in the PTAB decision to institute the AIA trial. The Court’s misinterpretation of the bar on appeals at 35 U.S.C. §314(d) conflicts with the presumption of judicial review of executive branch actions.
The BRI standard was specially crafted for examinational proceedings, not for the adjudicative proceedings created by the AIA. Congress intended those adjudicative proceedings to be an efficient alternative to district court trials, according to the brief, and they should follow the Phillips/Markman standard for claim construction used in district courts. The amicus brief also argued that the Federal Circuit incorrectly bars appellate consideration of issues raised in the PTAB final written decision when those issues were also addressed in the PTAB decision to institute the AIA trial. The Court’s misinterpretation of the bar on appeals at 35 U.S.C. §314(d) conflicts with the presumption of judicial review of executive branch actions.
Upcoming Events
-
2026 Patent Prosecution Bootcamp - Arlington, VA
March 4 to 6, 2026 | Up to 1235 minutes, including 60 Ethics minutes
-
2026 Trade Secret Summit
April 23 to 24, 2026
-
2026 Advanced Chemical & Biotech Patent Institute
May 11 to 12, 2026 | CLE calculations pending
The Advanced Chemical & Biotech Patent Institute is an in-depth continuing legal education program tailored specifically for experienced patent practitioners in the chemical and biotech fields. This advanced course offers a comprehensive view from both prosecution and litigation perspectives, covering crucial topics relevant to practice in the U.S. and internationally. -
2026 Spring Meeting - San Francisco, CA
May 13 to 15, 2026
We’re excited to welcome you to the 2026 AIPLA Spring Meeting, where innovation, technology, and intellectual property come together to shape the future. San Francisco is ready for your ideas, energy, and passion for IP! -
AIPLA 2026 Annual Meeting
October 29 to 31, 2026
Join us as we bring IP professionals together to learn and connect. More information coming soon! The 2026 Annual meeting will take place at the Westin Washington, DC, Downtown. Leadership Meetings on Wednesday, October 28. Programming scheduled October 29 - 31.
